[Comment] Evolution of front-line immunotherapy for metastatic urothelial cancer

In The Lancet Oncology, Enrique Grande and colleagues1 and Aristotelis Bamias and colleagues2 report the final results of IMvigor 130, a clinical trial exploring the role for checkpoint inhibition in the front-line treatment of locally advanced or metastatic surgically unresectable urothelial carcinoma. The investigators studied the use of atezolizumab as a single agent (group B) and in combination with standard-of-care platinum-based chemotherapy (group A), compared with placebo plus platinum-based chemotherapy (group C), in patients with previously untreated locally advanced or metastatic urothelial cancer.